Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Gripblocker Express
Cracking of the soft gelatin shell seams and leakage of the capsule fill into the blister pocket were found, creating a real risk to patients’ health through the possibility of taking an incomplete dose and lack of effectiveness of the medicinal product. Potencjalne skutki: lack of treatment effectiveness, worsening or prolongation of disease symptoms.
Maść szałwiowa
The lack of a correct authorization number on the packaging makes it impossible to verify if the product may be marketed in Poland and raises doubts about its authenticity. This situation may mislead users and poses a threat to public health. Potential effects: incorrect use of the medicine, lack of treatment efficacy, possible health complications.
Maść szałwiowa
The lack of a correct marketing authorisation number on the outer packaging makes it impossible to verify whether the product can be legally marketed in Poland and raises doubts about the authenticity of the medicine; it may mislead users, posing a threat to public health. Potential effects: inability to verify medicine authenticity, risk of using a product not compliant with its authorisation.
Konaten
Out-of-specification (OOS) results were found for atomoxetine content below the lower limit and, for one batch, non-compliant capsule mass uniformity, leading to a reduced dose of the medicine. Potential effects: reduced treatment efficacy, worsening of disease symptoms.
Konaten
for 7 of 41 batches marketed in Poland, out‑of‑specification results for atomoxetine content were found in reference samples, below the lower specification limit; the medical risk assessment indicated possible low effectiveness of the medicine. Potential effects: reduced therapeutic efficacy, risk of lack of the expected treatment effect.
Konaten
Out-of-specification (OOS) results were found for atomoxetine content, below the lower specification limit, and in one batch also non-compliance in the mass uniformity parameter. The risk assessment points mainly to a possibility of reduced treatment effectiveness. Potential effects: absence or reduction of therapeutic efficacy.
Konaten
For some batches reference samples showed out-of-specification atomoxetine content below the lower limit, and for one batch also non-compliant capsule mass uniformity. Potential effects: reduced treatment efficacy, risk of lack of therapeutic effect.
Konaten
Out-of-specification (OOS) results were found for atomoxetine content (below the lower limit) and, for one batch, failure in capsule mass uniformity, which may lead to administration of too low a dose of the active substance. Potential effects: reduced treatment efficacy, possible worsening of disease symptoms.
Konaten
Out-of-specification results were found for atomoxetine content, below the lower specification limit, and for one batch non‑compliant capsule mass uniformity; the risk assessment indicated mainly potentially reduced drug efficacy. Potential effects: lack of or reduced treatment effectiveness.
Konaten
Out-of-specification results were found in reference samples for atomoxetine content (outside the 95.0–105.0% range) and, in one case, for capsule mass, indicating variable active substance dosage. Potential effects: reduced treatment effectiveness or increased adverse reactions.
Konaten
Out-of-specification (OOS) results were found in reference samples for atomoxetine content, below the lower specification limit; for one batch also non-compliance in capsule mass uniformity; the impact on safety was assessed as low. Potential effects: reduced treatment effectiveness, possible worsening of symptoms, risk of complications due to poor disease control.
Monover
A clearly visible large piece of glass (about 1 cm) was found moving inside the vial, as well as glass particles on the walls and neck of the vial of a product administered intravenously. Potential effects: severe vascular complications, embolism, tissue damage, life‑threatening complications.
Eptifab
An incorrect dosing regimen for the medicinal product in solution for injection form, resulting from erroneous leaflet data, may cause direct adverse health consequences for patients, posing a real risk to health and potentially to life. Potential effects: overdose or insufficient efficacy, serious cardiovascular complications, life‑threatening events.
Gripblocker Express
A quality defect was found: cracking of the soft gelatin capsule seam and leakage of the fill into the blister pocket, risking intake of an incomplete dose and lack of therapeutic effectiveness. Potential effects: lack of efficacy, persistence or worsening of symptoms.
Acurenal
Stability testing and reference sample results showed that the batches covered by the decision do not meet the requirement for the parameter "Purity: content of impurity A", which constitutes a real and direct risk to patients' health or life. Potential effects: poisoning, lack of treatment efficacy, increased adverse effects.
Atofab
Out-of-specification results were found for atomoxetine content and non-uniform capsule mass in batches manufactured from the same bulk batches; risk assessment indicates possible reduced therapeutic efficacy. Potential effects: possible treatment failure and worsening of disease symptoms.
Acurenal
It was determined that batches 80219782 and 80212781 do not meet the requirements for the parameter “Purity: content of impurity A”, and exceeding the acceptance criteria was considered a real and direct threat to patients’ health or life. Potential effects: possible adverse effects, poisoning, lack of treatment safety.
Atofab
Out-of-specification (OOS) results were found in reference samples for the atomoxetine content parameter, which may affect the quality and effectiveness of the medicine. Potential effects: lack or reduced treatment efficacy, possible worsening of disease symptom control.
Osporil
The National Medicines Institute found in batch ZD033 the presence of particles visible to the naked eye in a solution administered by intravenous infusion; any exceedance of quality criteria constitutes a real and direct threat to patients' health or life. Potential effects: embolic complications, inflammatory reactions, life-threatening events.
Viglita
This product did not meet its defined quality requirements due to a negative test result for the friability of uncoated tablets ("tablets crumbled after the test"). Potential effects: possible problems with dosing and treatment effectiveness.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.